Funding for this research was provided by:
National Institutes of Health (1S10OD012304-01)
University of Houston (Moores Chair funds)
Cancer Prevention and Research Institute of Texas (180259, RP200423)
Baylor College of Medicine (Agilent Technologies Center of Excellence in Mass Spectrometry)
National Cancer Institute (1R01CA218025-01, 1R01CA231011-01, 1R01CA218036-01)
U.S. Department of Defense (BC180196, BC181384)
University of Texas MD Anderson Cancer Center (Andrew Sabin Family Foundation Fellows award)
American Association for Cancer Research (20-60-51 Yang)
Received: 30 December 2020
Accepted: 9 July 2021
First Online: 28 August 2021
: All animal-based research was conducted according to the guidelines and requirements set forth by the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals, the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act of 1966 as amended by the Institutional Animal Care and Use Committee (IACUC) of the University of Texas M.D. Anderson Cancer Center (MDACC). All of the human specimen-related studies have been approved by the Institutional Review Board of The University of Texas, MD Anderson Cancer Center. De-identified fresh-frozen human skeletal muscle tissues were commercially obtained from ProteoGenex Inc. All hiPSC-related studies were approved by the Human Embryonic & Induced Pluripotent Stem Cell Research Oversight committee of The University of Texas, MD Anderson Cancer Center.
: Not applicable.
: Zhen Xing is now an employee of Sanofi U.S. The remaining authors declare that they have no competing interests.